A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Ontology highlight
ABSTRACT: DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.
DISEASE(S): Colorectal Neoplasms,Pancreatic Neoplasms,Lung Neoplasms,Neoplasms,Solid Tumors
PROVIDER: 2177400 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA